Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy

Abstract

Background Interferon-alpha therapy, which is used to treat metastatic malignant melanoma, can cause patients to develop two distinct neurobehavioral symptom complexes: a mood syndrome and a neurovegetative syndrome. Interferon-alpha effects on serotonin metabolism appear to contribute to the mood and anxiety syndrome, while the neurovegetative syndrome appears to be related to interferon-alpha effects on dopamine. Purpose Our goal is to propose a design for utilizing a sequential, multiple assignment, randomized trial design for patients with malignant melanoma to test the relative efficacy of drugs that target serotonin versus dopamine metabolism during 4 weeks of intravenous, then 8 weeks of subcutaneous, interferon-alpha therapy. Methods Patients will be offered participation in a double-blinded, randomized, controlled, 14-week trial involving two treatment phases. During the first month of intravenous interferon-alpha therapy, we will test the hypotheses that escitalopram will be more effective in reducing depressed mood, anxiety, and irritability, whereas methylphenidate will be more effective in diminishing interferon-alpha-induced neurovegetative symptoms, such as fatigue and psychomotor slowing. During the next 8 weeks of subcutaneous interferon therapy, participants whose symptoms do not improve significantly will be randomized to the alternate agent alone versus escitalopram and methylphenidate together. Results We present a prototype for a single-center, sequential, multiple assignment, randomized trial, which seeks to determine the efficacy of sequenced and targeted treatment for the two distinct symptom complexes suffered by patients treated with interferon-alpha. Limitations Because we cannot completely control for external factors, a relevant question is whether or not ‘short-term’ neuropsychiatric interventions can increase the number of interferon-alpha doses tolerated and improve long-term survival. Conclusions This sequential, multiple assignment, randomized trial proposes a framework for developing optimal treatment strategies; however, additional studies are needed to determine the best strategy for treating or preventing neurobehavioral symptoms induced by the immunotherapy interferon-alpha.

Neurobehavioral Effects of Interferon-α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine

“…The resulting information may then ultimately improve the treatment of IFN-a-treated patients, and other medically ill persons with prolonged neurovegetative symptoms induced by innate immune system activation (Auyeung et al, 2009).…”

Design and analysis considerations for comparing dynamic treatment regimens with binary outcomes from sequential multiple assignment randomized trials

“…This may occur in trials, for example in oncology, where the second-stage intervention is a maintenance intervention and there are no further options for those who do not respond to the first-stage intervention. Examples of design II in practice include investigations of the treatment of ADHD [40], acute myelogenous leukemia [45, 46], small-cell lung cancer [48], neuroblastoma [29, 30], diffuse large cell lymphoma [15], multiple myeloma [28], and metastatic malignant melanoma [5]. There are four DTRs embedded in this design: (1,0,1), (1,0,0), (0,0,1), and (0,0,0).…”

SMART designs in cancer research: Past, present, and future

“…More recent SMARTs, [36] and [35], were designed to develop and compare DTRs. These designs, analysis plans, and eventual results provide concrete examples of cancer SMARTs addressing global treatment questions by developing personalized decision rules.…”